AQR Capital Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

AQR Capital Management’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-62,723	Closed	-$226K	–	2252
2019 Q1	$226K	Buy	+62,723	New	+$272K	﹤0.01%	2045
2018 Q1	–	Sell	-24,421	Closed	-$128K	–	2314
2017 Q4	$128K	Hold	24,421	–	–	﹤0.01%	2191
2017 Q3	$150K	Sell	24,421 -9,811	-29%	-$62.1K	﹤0.01%	2199
2017 Q2	$247K	Hold	34,232	–	–	﹤0.01%	2082
2017 Q1	$181K	Sell	34,232 -30,847	-47%	-$208K	﹤0.01%	2124
2016 Q4	$467K	Buy	65,079 +29,306	+82%	+$237K	﹤0.01%	1958
2016 Q3	$335K	Buy	+35,773	New	+$297K	﹤0.01%	2055
2016 Q2	–	Sell	-61,485	Closed	-$339K	–	2303
2016 Q1	$339K	Sell	61,485 -3,792	-6%	-$14.3K	﹤0.01%	1962
2015 Q4	$364K	Buy	65,277 +28,723	+79%	+$190K	﹤0.01%	1984
2015 Q3	$309K	Buy	+36,554	New	+$619K	﹤0.01%	1914
2014 Q4	–	Sell	-10,000	Closed	-$100K	–	2685
2014 Q3	$100K	Buy	+10,000	New	+$121K	﹤0.01%	2442

Other funds holding PETX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OAC

OMERS Administration Corp Toronto, Ontario, Canada $15.6B AUM 24.73% 1-Year Est. Return

AQR Capital Management's PETX Position: Q2 2019 in Review

AQR Capital Management sold out of Aratana Therapeutics, Inc. (PETX) in Q2 2019, closing a stake of 62,723 shares — an estimated $226K sold.

AQR Capital Management first reported a position in PETX in Q3 2014 and held it in 11 quarters. The position peaked at $467K in Q4 2016. 103 funds tracked by Wall St. Rank hold PETX as of Q2 2019.

AQR Capital Management reported no remaining Aratana Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
AQR Capital Management sold 62,723 Aratana Therapeutics, Inc. shares in Q2 2019, an estimated $226K.
AQR Capital Management first reported a position in Aratana Therapeutics, Inc. in Q3 2014 and held it in 11 quarters.
AQR Capital Management's Aratana Therapeutics, Inc. position peaked at $467K in Q4 2016.
103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q2 2019.

Based on AQR Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.